ライフサイエンスコーパス: dihydropyrimidine dehydrogenase

1 reased pyrimidine catabolism at the level of dihydropyrimidine dehydrogenase.

2 tumours, consistent with the inactivation of dihydropyrimidine dehydrogenase: a selective decrease in

3 Eniluracil (776C85), a potent inactivator of dihydropyrimidine dehydrogenase, allows fluorouracil (5-

4 ples include thiopurine S-methyltransferase, dihydropyrimidine dehydrogenase and flavin monooxygenase

5 5-Fluorouracil is inactivated by dihydropyrimidine dehydrogenase and targets thymidylate

6 Dihydropyrimidine dehydrogenase catalyzes the rate-limit

7 bolite 5-methyl tetrahydrofolate (MTHF), and dihydropyrimidine dehydrogenase (DPD) activity in periph

8 Dihydropyrimidine dehydrogenase (DPD) activity was deter

9 Dihydropyrimidine dehydrogenase (DPD) catabolizes endoge

10 Dihydropyrimidine dehydrogenase (DPD) deficiency constit

11 cause of intolerance to fluoropyrimidines is dihydropyrimidine dehydrogenase (DPD) deficiency, which

12 rt that macrophages specifically overexpress dihydropyrimidine dehydrogenase (DPD) in hypoxia, leadin

13 Dihydropyrimidine dehydrogenase (DPD) is a major determi

14 Dihydropyrimidine dehydrogenase (DPD) is the initial and

15 Dihydropyrimidine dehydrogenase (DPD) is the initial, ra

16 ve reported a correlation between intratumor dihydropyrimidine dehydrogenase (DPD) messenger RNA (mRN

17 ected dose of 5-FU is rapidly inactivated by dihydropyrimidine dehydrogenase (DPD) to therapeutically

18 ficiency of the pyrimidine catabolic enzyme, dihydropyrimidine dehydrogenase (DPD), has been shown to

19 e uracil in UFT slows degradation of 5-FU by dihydropyrimidine dehydrogenase (DPD), which results in

20 e pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) express

21 Dihydropyrimidine dehydrogenase (DPD, encoded by DPYD) r

22 in the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie, DPYD*2A) is st

23 ral regimen of eniluracil (which inactivates dihydropyrimidine dehydrogenase [DPD]), 5-FU, and leucov

24 enzyme in the pyrimidine catabolic pathway, dihydropyrimidine dehydrogenase (DPYD) and its effect on

25 Dihydropyrimidine dehydrogenase (DPYD) is an enzyme resp

26 n addition, AEG-1 enhances the expression of dihydropyrimidine dehydrogenase (DPYD) that catalyzes th

27 Dihydropyrimidine dehydrogenase (DPYD), a pyrimidine-deg

28 sly unreported gene affecting sleep duration-dihydropyrimidine dehydrogenase (Dpyd).

29 red study with eniluracil, an inactivator of dihydropyrimidine dehydrogenase, enabling catabolite cor

30 Thus, by inactivating dihydropyrimidine dehydrogenase, EU prolonged the half-l

31 Tumoral dihydropyrimidine dehydrogenase expression is a promisin

32 acy; in the XELOX group, for high versus low dihydropyrimidine dehydrogenase expression levels, DFS H

33 shown the prognostic impact of several rare dihydropyrimidine dehydrogenase gene (DPYD) variants on

34 The dihydropyrimidine dehydrogenase gene (DPYD) was isolated

35 xia induces HIF2a-mediated overexpression of dihydropyrimidine dehydrogenase in TAMs, leading to chem

36 e to progression (TTP) of an oral regimen of dihydropyrimidine dehydrogenase inhibitory fluoropyrimid

37 Low tumor expression of dihydropyrimidine dehydrogenase may be predictive for XE

38 pidermal growth factor receptor mutation, or dihydropyrimidine dehydrogenase polymorphism) may differ

39 and other drug metabolizing enzymes such as dihydropyrimidine dehydrogenase represents a major innov

40 acil (776C85) is an effective inactivator of dihydropyrimidine dehydrogenase that allows continuous l

41 acil is being developed as an inactivator of dihydropyrimidine dehydrogenase, the enzyme that brings

42 routine use of p53, ras, thymidine synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase